Effects of activated protein C on the mesenteric microcirculation and cytokine release during experimental endotoxemia

Canadian Journal of Anesthesia

Volumn 55, Issue 3, 2008, Pages 155-162

  Lehmann, Christian ^a,b   Scheibe, Ricardo ^b   Schade, Michael ^b   Meissner, Konrad ^b,c   Gründling, Matthias ^b   Usichenko, Taras ^b   Wendt, Michael ^b   Hung, Orlando ^a   Whynot, Sara ^a   Murphy, Michael ^a   Pavlovic, Dragan ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; BLOOD LEVEL; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENDOTHELIUM; ENDOTOXEMIA; EXTRAVASATION; FLUORESCENCE MICROSCOPY; LEUKOCYTE; LEUKOCYTE ADHERENCE; MESENTERY BLOOD FLOW; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 41349087530     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03016089     Document Type: Article

References (25)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-54.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
3. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
4. Walker FJ, Sexton PW, Esmon CT. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 1979; 571: 333-42.
5. Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Crit Care Med 2001; 29(7 Suppl): S69-74.
6. Lehmann C, Meissner K, Knock A, et al. Activated protein C improves intestinal microcirculation in experimental endotoxaemia in the rat. Crit Care 2006; 10: R157.
7. Clark JA, Coopersmith CM. Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness. Shock 2007; 28: 384-93.
8. Birnbaum J, Hein OV, Luhrs C, et al. Effects of coagulation factor XIII on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation in experimental endotoxemia. Crit Care 2006; 10: R29.
9. Iba T, Kidokoro A, Fukunaga M, Nagakari K, Shirahama A, Ida Y. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med 2005; 33: 368-72.
10. Pavlovic D, Frieling H, Lauer KS, et al. Thermostatic tissue platform for intravital microscopy: 'the hanging drop' model. J Microsc 2006; 224: 203-10.
11. Lehmann C, Konig JP, Dettmann J, Birnbaum J, Kox WJ. Effects of iloprost, a stable prostacyclin analog, on intestinal leukocyte adherence and microvascular blood flow in rat experimental endotoxemia. Crit Care Med 2001; 29: 1412-6.
12. Lehmann C, Birnbaum J, Luhrs C, et al. Effects of C1 esterase inhibitor administration on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation during experimental endotoxemia. Intensive Care Med 2004; 30: 309-14.
13. Grinnell BW, Hermann RB, Yan SB. Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. Glycobiology 1994; 4: 221-5.
14. Murakami K, Okajima K, Uchiba M, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996; 87: 642-7.
15. Hoffmann JN, Vollmar B, Laschke MW, et al. Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 2004; 32: 1011-7.
16. Yadav R, Larbi KY, Young RE, Nourshargh S. Migration of leukocytes through the vessel wall and beyond. Thromb Haemost 2003; 90: 598-606.
17. Liu L, Kubes P. Molecular mechanisms of leukocyte recruitment: organ-specific mechanisms of action. Thromb Haemost 2003; 89: 213-20.
18. Weber C. Novel mechanistic concepts for the control of leukocyte transmigration: specialization of integrins, chemokines, and junctional molecules. J Mol Med 2003; 81: 4-19.
19. Piper RD, Pitt-Hyde ML, Anderson LA, Sibbald WJ, Potter RF. Leukocyte activation and flow behavior in rat skeletal muscle in sepsis. Am J Respir Crit Care Med 1998; 157: 129-34.
20. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-78.
21. Macias WL, Yan SB, Williams MD, et al. New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 2005; (9 Suppl 4): S38-45.
22. Mizutani A, Okajima K, Uchiba M, Noguchi T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000; 95: 3781-7.
23. Choi G, Hofstra JJ, Roelofs JJ, et al. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 2007; 35: 1362-8.
24. Jesch NK, Dorger M, Messmer K, Krombach F. Formation of nitric oxide by rat and hamster alveolar macrophages: an interstrain and interspecies comparison. Toxicol Lett 1998; 96-97: 47-51.
25. Deschepper CF, Olson JL, Otis M, Gallo-Payet N. Characterization of blood pressure and morphological traits in cardiovascular-related organs in 13 different inbred mouse strains. J Appl Physiol 2004; 97: 369-76.